Johnson & Johnson $JNJ Shares Sold by Intrepid Financial Planning Group LLC

Intrepid Financial Planning Group LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 10,558 shares of the company’s stock after selling 273 shares during the period. Intrepid Financial Planning Group LLC’s holdings in Johnson & Johnson were worth $1,613,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter worth about $48,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson in the first quarter valued at about $52,000. Finally, Pandora Wealth Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on JNJ. Argus set a $210.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Bank of America raised their price target on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Scotiabank initiated coverage on Johnson & Johnson in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price target for the company. Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Finally, Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Four research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Stock Up 0.3%

JNJ opened at $200.10 on Wednesday. The firm has a market cap of $482.11 billion, a P/E ratio of 19.31, a PEG ratio of 2.19 and a beta of 0.38. The business’s fifty day simple moving average is $186.69 and its 200 day simple moving average is $170.77. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $200.30. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.